Generic Name: ixazomib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).
Ninlaro is a proteasome inhibitor that targets an enzyme that digests and eliminates excess proteins in myeloma cells. Blocking proteasome activity leads to myeloma cell death.
Clinical trials showed that Ninlaro in combination with other medications slows progression of multiple myeloma.
Ninlaro is a pill taken on days 1, 8 and 15 in a monthly cycle. It should be taken at least one hour before or at least two hours after food.
Common side effects include diarrhea, constipation, nausea, peripheral neuropathy, swelling, back pain and depletion of platelets (thrombocytopenia), which can lead to easy bleeding. It can cause birth defects and should not be used during pregnancy.
For More Info: https://www.ninlaro.com
Co-Pay Program Info: https://www.ninlaro.com/financial-resources
Patient Assistance Program Info: https://www.ninlaro.com/financial-resources
Last Reviewed: September 18, 2018